CRRTF Stock Crescita Therapeutics (CRRTF, $0.32) was a top quarterly gainer, rising +35.28%. Expect an Uptrend reversal

GET DAILY SIGNALS

Get AI intraday signals

CRRTF - Crescita Therapeutics Inc

3-month gain

View

Odds of DOWN Trend

Loading...

Price: $0.3207

Daily change: -$0.02 (-5.87%)

Daily volume: 22.2K

3-month price change: +$0.083632 (+35.28%)

Capitalization: $6.1M

Industry: Pharmaceuticals: Generic

Crescita Therapeutics (CRRTF, $0.32) was one of top quarterly gainers, jumping +3 to $0.32 per share. A.I.dvisor analyzed 225 stocks in the Pharmaceuticals: Generic Industry over the last three months, and discovered that of them () charted an Uptrend while of them () trended down. A.I.dvisor found 204 similar cases when CRRTF's price went up within three months. In out of those 204 cases, CRRTF's price went down during the following month. Based on these historical data, A.I. thinks the odds of an Uptrend reversal for CRRTF are

CRRTF's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for CRRTF turned positive on October 17, 2025. Looking at past instances where CRRTF's MACD turned positive, the stock continued to rise in of 29 cases over the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 16, 2025. You may want to consider a long position or call options on CRRTF as a result. In of 53 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

CRRTF moved above its 50-day moving average on November 05, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CRRTF crossed bullishly above the 50-day moving average on November 11, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Aroon Indicator for CRRTF entered a downward trend on November 04, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.593) is normal, around the industry mean (18.827). P/E Ratio (0.000) is within average values for comparable stocks, (71.764). CRRTF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.856). CRRTF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (0.462) is also within normal values, averaging (39.291).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CRRTF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRRTF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.